British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for gastrointestinal stromal tumours, contributing to GSK's expanding portfolio in gastrointestinal cancers amid its vaccine business challenges.
